0000000000540994

AUTHOR

Marianna Lo Re

showing 22 related works from this author

Clinical features and disease out come in patients with pediatric and young adult onset Multiple Sclerosis

2012

pediatric Multiple sclerosis young onsetSettore MED/26 - Neurologia
researchProduct

PREGNANCIES MODIFY RELAPSES AND PROGRESSION IN MULTIPLE SCLEROSIS

2014

Multiple sclerosisSettore MED/26 - Neurologia
researchProduct

Primary Progressive and progressive relapsing multiple sclerosis show different clinical and instrumental findings and disability progression? A comp…

2013

Multiple Sclerosis Progression Sicilian databaseSettore MED/26 - Neurologia
researchProduct

Clinical features, disease course and prognosis in patients with paediatric and young adult onset multiple sclerosis

2013

Background. Multiple sclerosis (MS) patients develop their first symptoms before adolescence approximately in 5%. Studies comparing clinical and prognostic characteristics in early onset MS, did not show homogeneous results. Objective. Aim of this study was to investigate characteristics of early onset MS patients and compare them with patients who experienced MS onset later. Methods. MS patients diagnosed as affected by MS according to Poser's criteria, were included if they experienced symptoms onset before age 25. They were classified in three groups. Group A: patients who had their onset until they were 16 years old Group B: individuals with onset between 17 and 20 yearsGroup C: patient…

Settore MED/26 - NeurologiaPediatric Multiple Sclerosis Epidemiology Prognosis
researchProduct

Hypoxanthine and purine compounds in plasma from patients with multiple sclerosis and psoriasis

2011

HypoxanthineSettore BIO/10 - BiochimicaPsoriasisMultiple sclerosiSettore MED/26 - NeurologiaHypoxanthine; Multiple sclerosis; Psoriasis
researchProduct

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers

2015

Introduction Natalizumab (NTZ) discontinuation can be followed by multiple sclerosis (MS) disease reactivation. Currently no disease-modifying drug (DMD) has been shown to be able to abolish disease reactivation. The aims of the current study were: (1) to determine the frequency of MS reactivation after NTZ discontinuation; (2) to evaluate predictors of reactivation risk, and (3) to compare the effect of different treatments in reducing this risk. Methods Data from 132 patients with MS followed-up for 2 years before NTZ treatment and 1 year after interruption were collected from two Italian MS centers and retrospectively evaluated. Results Overall, 72 of 132 patients (54.5%) had relapses af…

medicine.medical_specialtyNeurologyNatalizumab discontinuationDiseasePharmacologyMultiple sclerosisNatalizumabInternal medicineparasitic diseasesDisease reactivationmedicineMultiple sclerosiIn patientFirst-line therapieOriginal ResearchDisease reactivation; First-line therapies; Multiple sclerosis; Natalizumab discontinuation; Rebound; Second-line therapies; Neurology (clinical); NeurologyFirst-line therapiesReboundSecond-line therapiebusiness.industryMultiple sclerosisRetrospective cohort studymedicine.diseaseDiscontinuationNeurologyTreatment strategyNeurology (clinical)businessSecond-line therapiesmedicine.drug
researchProduct

Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study

2017

Abstract Background The association between multiple sclerosis (MS) and cancer has long been investigated with conflicting results. Several reports suggest an increased cancer risk among MS patients treated with immunosuppressant (IS) drugs. Methods We performed a cohort study including MS patients recruited at the Neurological Department of the University of Palermo. Mean follow-up period was ten years for the whole cohort. We calculated cancer incidence among patients treated with IS. Incidence rates were compared in the cohort by calculating the relative risk according to length and dose of exposure to IS. Cancer incidence among MS patients was compared to cancer incidence in the general…

AdultMaleRiskmedicine.medical_specialtyMultiple SclerosisPopulationlcsh:RC346-429Cohort StudiesYoung Adult03 medical and health sciences0302 clinical medicineNeoplasmsInternal medicinemedicineHumansMultiple sclerosiCancer; Cohort study; Immunosuppressant; Multiple sclerosis; Treatment; Neurology (clinical)Prospective cohort studyeducationlcsh:Neurology. Diseases of the nervous systemCancerImmunosuppressanteducation.field_of_studybusiness.industryIncidenceMultiple sclerosisCancerRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment030220 oncology & carcinogenesisRelative riskCohortFemaleNeurology (clinical)Cohort studybusinessImmunosuppressive Agents030217 neurology & neurosurgeryResearch ArticleCohort studyBMC Neurology
researchProduct

Cyclophosphamide Pulse Therapy after Natalizumab Discontinuation for Multiple Sclerosis: a multicenter study.

2015

Importance: Natalizumab discontinuation induces the recurrence of Multiple Sclerosis (MS) disease activity: Currently no therapeutic approach has been found able to abolish disease reactivation. Objective: To collect data from patients with MS switching from natalizumab to cyclophosphamide. Design: Retrospective multicentre study. Setting: Nine Multiple Sclerosis Centers in Italy. Participants: A total of 47 patients with clinically definite RR-MS switched to cyclophosphamide after natalizumab discontinuation. Two patients were excluded from the analysis because received less than 12 natalizumab infusions. The remaining 45 patients were subdivided into two main groups: Early Treatment (peri…

medicine.medical_specialtyExpanded Disability Status ScaleCyclophosphamidebusiness.industryMultiple sclerosismedicine.diseaseOmicsDiscontinuationMultiple sclerosis; Natalizumab discontinuation; Disease reactivation; Cyclophosphamide; ReboundNatalizumabInternal medicineImmunologymedicineBrain magnetic resonance imagingbusinessAdverse effectmedicine.drug
researchProduct

Reversible posterior leukoencephalopathy syndrome in a patient with thrombotic thrombocytopenic purpura

2011

Thrombotic thrombocytopenic purpura (TTP) is an autoimmune disorder characterised by fever, microangiopathic haemolytic anaemia, renal insufficiency, and thrombocytopenia. Neurological involvement, a prominent component of TTP, is characterised by a variety of brain lesions which include reversible cerebral oedema or magnetic resonance imaging (MRI) features of reversible posterior leukoencephalopathy syndrome (RPLS). TTP is frequently associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13.Here, we report a case of TTP with severe acute encephalopathy. Posterior leukoencephalopathy and brainstem oedema with triventricular hydrocephalus were observed on MRI. The …

Malemedicine.medical_specialtyPathologyNeurologyThrombotic thrombocytopenic purpuraAnti-Inflammatory AgentsDermatologyMethylprednisolonehemic and lymphatic diseasesmedicineHumansmedicine.diagnostic_testbusiness.industryMagnetic resonance imagingGeneral MedicinePlasmapheresisMiddle Agedmedicine.diseaseReversible posterior leukoencephalopathy Thrombotic thrombocytopenic purpura ADAMTS-13Plasma exchangeADAMTS13SchistocyteSurgeryHydrocephalusPsychiatry and Mental healthPurpuraTreatment OutcomeMethylprednisolonePurpura ThrombocytopenicSettore MED/26 - NeurologiaNeurology (clinical)Posterior Leukoencephalopathy Syndromemedicine.symptombusinessmedicine.drug
researchProduct

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.

2021

Objective: To identify baseline factors associated with disease activity in patients with relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. Methods: This was an independent, multi-centre, retrospective post-marketing study. We analysed data of 1,507 patients who started teriflunomide since October 2014 and were regularly followed in 28 Centres in Italy. We reported the proportions of patients who discontinued treatment (after excluding 32 lost to follow-up) and who experienced clinical disease activity, i.e., relapse(s) and/or confirmed disability worsening, as assessed by the Expanded Disability Status Scale (EDSS). Decision tree-based analysis was performed to i…

medicine.medical_specialtyNeurologyMultiple SclerosisToluidinesHydroxybutyratesOral drugsDiseaseRelapsing-RemittingSettore MED/26Pregnancy planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideTeriflunomideNitrilesmedicineHumans030212 general & internal medicineAdverse effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosismedicine.diseaseSettore MED/26 - NEUROLOGIANeurologychemistryTolerabilityItalyMultiple sclerosis; Oral drugs; Teriflunomide; Crotonates; Humans; Hydroxybutyrates; Italy; Nitriles; Retrospective Studies; Toluidines; Multiple Sclerosis; Multiple Sclerosis Relapsing-RemittingCrotonatesNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology
researchProduct

IMMUNOSUPPRESSANT TREATMENT AND CANCER RISK IN A COHORT OF PATIENTS AFFECTED BY MULTIPLE SCLEROSIS

2011

CANCER RISKSettore MED/26 - NeurologiaMULTIPLE SCLEROSIS
researchProduct

Clinical and instrumental predictors of efficacy of natalizumab therapy in the course of multiple sclerosis: a retrospective study from a single cent…

2013

Multiple sclerosis episodemiology disease courseSettore MED/26 - Neurologia
researchProduct

SIMULTANEOUS DETERMINATION OF ATP, ITS METABOLITES AND NAD+ IN BLOOD BY HPLC WITH PHOTODIODE ARRAY DETECTOR

2013

SIMULTANEOUS DETERMINATION OF ATP, ITS METABOLITES AND NAD+ IN BLOOD BY HPLC WITH PHOTODIODE ARRAY DETECTOR Gueli Maria Concetta, Cusimano Vincenza, Lo Re Marianna, Giuseppe Salemi Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (BioNEC), Università degli Studi di Palermo. Nucleotides are major high-energy phosphate carriers, subunits of nucleic acids and precursors for the synthesis of nucleotide cofactors such as NAD+ and SAM. The study of purine nucleotides metabolism is very important topic for a right understanding for the cellular life. Living cells rely on ATP for growth, differentiation, and response to physiological stimuli and environmental stress. We propose a fa…

Photodiode Array DetectorSettore BIO/10 - BiochimicaHPLCNucleotide
researchProduct

Return of disease activity after natalizumab therapy discontinuation in patients with multiple sclerosis: frequency and clinical and instrumental pre…

2012

Settore MED/26 - NeurologiaMultiple sclerosis natalizumab therapy
researchProduct

Causes and place of death in Italian patients with amyotrophic lateral sclerosis

2010

Objectives - To determine the causes and place of death in a cohort of Italian patients with amyotrophic lateral sclerosis (ALS). A better understanding of the likely causes of death in ALS might improve the palliative care at the end-of-life, whereas knowing the place of death will help to verify the need for highly specialized care services, e.g. hospice and nursing home. Patients and methods - Between 2000 and 2008, 182 ALS patients (onset: spinal, 127; bulbar, 55; M/F: 1.6) were followed in a single ALS Tertiary Centre in Palermo, Sicily, Italy until death. Medical data for each individual patient were recorded in a large database throughout the disease course. Information concerning ca…

MaleDATABASEUNITED-STATESKaplan-Meier EstimateCohort StudiesResidence CharacteristicsCause of DeathHumansEPIDEMIOLOGYPOPULATIONAgedRetrospective StudiesChi-Square DistributionAmyotrophic Lateral SclerosisNATURAL-HISTORYMiddle AgedCAREALS death epidemiologyLIFEdeathsItalyENDSURVIVALSettore MED/26 - NeurologiaFemaleALSRespiratory Insufficiency
researchProduct

Extracellular vesicles isolated by cerebrospinal fluid as biomarkers of inflammation in multiple sclerosis and inflammatory neurological diseases.

2014

multiple sclerosimicrovesiclebiomarkerSettore MED/26 - Neurologiacerebrospinal fluid
researchProduct

Clinical and Instrumental Findings and Disability Progression in Primary Progressive and Progressive Relapsing Multiple Sclerosis: A Comparison Study…

2013

Primary Progressive Multiple Sclerosis Progressive relapsing multiple sclerosisSettore MED/26 - Neurologia
researchProduct

Purine metabolism and multiple sclerosis: pattern varies according to disease stage and clinical form

2013

multiple sclerosis purine metabolism
researchProduct

Clinical and instrumental predictors of efficacy of Natalizumab therapy in multiple sclerosis patients: a retrospective study from a single centre

2012

Natalizumab Multiple sclerosisSettore MED/26 - Neurologia
researchProduct

Frequency of John Cunningham virus (JCV) DNA and of antibodies against JCV in patients affected by multiple sclerosis and their relationship with nat…

2012

JCV virus Natalizumab Multiple SclerosisSettore MED/26 - Neurologia
researchProduct

Purine metabolism and Multiple Sclerosis: different pattern according to different disease stage and different clinical form.

2013

P422 Purine metabolism and multiple sclerosis: pattern varies according to disease stage and clinical form G. Salemi, M. Gueli, V. Cusimano, M. Lo Re, V. Lo Re, M.A. Mazzola, S. Realmuto, P. Ragonese, G. Savettieri University (Palermo, IT) Background: Serum concentration of uric acid (sUA) was variably associated with Multiple Sclerosis (MS). Many papers reported lower sUA in MS patients respect to healthy controls, expecially in course of relapse. This lower sUA was considered as a marker of oxidative stress. However, this association was not confirmed by many other papers. Recently, an increase in the concentration of sUA, hypoxanthine, xanthine, and sum of oxypurine (sPU) was reported in…

Multiple SclerosisPurine metabolismSettore BIO/10 - BiochimicaSettore MED/26 - Neurologia
researchProduct

A CASE OF JUVENILE STROKE CAUSED BY ACTINIC CERVICAL ARTERIOPATHY

2013

Introduction: Radiation Arteriopathy is a vascular disease characterized by progressive arterial stenosis that may occur after external radiotherapy (RT) directed to a specific body region affected by malignant tumours. The arterial damage usually starts many years after the injury and the specific pathogenesis is unknown, though atherosclerosis praecox, endothelial damage, adventitial fibrosis and vasa vasorum obliteration are likely involved mechanisms. In patients with previously irradiated neck or head cancers, supra aortic arteries can be affected in their segments exposed to radiations leading to a gradual lumen narrowing. This late complication leads to a progressive stenosis of extr…

acute juvenile strokeRadiation Arteriopathy
researchProduct